Lasa Supergenerics Ltd - 540702 - Half Yearly Certificate From Practicing Company Secretary Under Reg 40(9) Of SEBI (LODR) Regulation 2015
Regulation 40(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 we are enclosing herewith the certificate from Amit R. Dadheech & Associates, Practicing Company Secretary for the half year ended March 31, 2020. Lasa Supergenerics Ltd - 540702 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter and year ended March 31, 2020 received from Bigshare Services Private Limited, Registrar and Share Transfer Agent of the Company Lasa Supergenerics Ltd - 540702 - Announcement Under Regulation 30 (LODR)- Fight Against Corona
efforts to support government to prevent deadly covid19 Lasa Supergenerics Ltd - 540702 - Statement Of Investor Complaints For The Quarter Ended March 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- NIDHI KULSHRESTHADesignation :- Company Secretary and Compliance Officer Lasa Supergenerics Ltd - 540702 - Shareholding for the Period Ended March 31, 2020
Lasa Supergenerics Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2020. For more details, kindly Click here Lasa Supergenerics jumps 5% on USFDA nod
The drug will be manufactured at its WHO GMP certified facility at Mahad Industrial Area. Lasa Supergenerics Ltd - 540702 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lasa receives FDA nod for progesterone' Lasa Supergenerics Ltd - 540702 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lasa pledge to contribute for fight against COVID 19 Lasa Supergenerics Ltd - 540702 - Closure of Trading Window
the trading window for dealing in the equity shares of the Company shall remain closed for designated employees and their immediate relatives w.e.f. March 31, 2020 till 48 hours after the declaration of financial results Lasa Supergenerics to invest 50 cr to tackle the virus
Active Pharmaceutical Ingredients producer Lasa Supergenerics is looking at infusing 50 crore for developing Favipiravir, an anti-viral drug, which